Ion Exchange (India) Ltd
Ion Exchange (India) Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
What the Q4 FY26 call signalled
2 of 5 strong
The short version
The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports. Engineering segment expected to benefit from healthy order book and project execution, including significant projects like the IOCL Panipat Refinery and Oman BOOT contract, ensuring revenue growth.
From Ion Exchange (India) Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports.
- Roha plant aims for 25% capacity utilization in the first full year, with progressive customer acquisitions underway, supporting volume growth.
- Efforts are ongoing to grow revenues in the consumer products division, which increased 34% YoY, aiming to move towards breakeven or modest profitability.
- Engineering segment order book provides healthy revenue visibility, boosted by new medium-sized opportunities across sectors and international markets.
- The UP Jal Jeevan Mission and legacy projects will contribute revenue over the next financial year with expected execution ramp-up as government funding improves.
2 more points from Ion Exchange (India) Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ion Exchange (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Roha Plant: Focus on utilizing existing Roha facility capacity with backward integration underway; no major new CAPEX planned immediately, only maintenance and routine CAPEX of Rs.30-40 crores for FY27.
- Oman Project: CAPEX of around USD 40 million over next two years planned, funded by a mix of debt and equity; Ion Exchange holds 51% in the JV.
- Strategic Investments: Partnership with MANN+HUMMEL to expand membrane technology portfolio for global markets.
2 more points from Ion Exchange (India) Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Ion Exchange (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of 31st March 2026, the engineering order book stood at INR 26,433 million, providing healthy revenue visibility going forward.
- The company’s order intake in the engineering segment has been quite healthy, with a 40% increase compared to the last full financial year.
- Major portion of the projects from this order book are expected to be executed in the current and next financial year.
- The backlog includes standalone orders only; joint venture orders such as those in Oman are excluded from reported backlog.
2 more points from Ion Exchange (India) Ltd's call on order book
Create a free account to keep reading this call
Ion Exchange (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹863 Cr, net profit ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ION Exchange's management said in earlier quarters
Others in Other Utilities this season
- Sattva Engineering Construction Ltd (Q4 FY26)
Current order book as of May 2026 is INR447 crores, up from INR323 crores in March 2026. Key concall takeaways from Sattva Engineering Construction Ltd's Q4…
- Race Eco (Q4 FY26)
Q4 FY26 consolidated operating revenue: ₹108.25 crore, up 36.2% YoY (Page 4) . Key investor presentation takeaways from Race Eco's Q4 FY26 investor presentation
- Greenleaf Envi. (Q4 FY26)
Government allocation of INR 94,000 crore for water/wastewater infrastructure underpins steady demand. Key concall takeaways from Greenleaf Envirotech's Q4 FY26
- Sattva Engineering Construction Ltd (Q4 FY26)
Current order book increased from INR 323 crores (March 31, 2026) to INR 447 crores (May 15, 2026). Key concall takeaways from Sattva Engineering Construction's
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ion Exchange (India) Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ion Exchange (India) Ltd Q4 FY26 results?
The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports. Engineering segment expected to benefit from healthy order book and project execution, including significant projects like the IOCL Panipat Refinery and Oman BOOT contract, ensuring revenue growth.
What is Ion Exchange (India) Ltd share price analysis?
Ion Exchange (India) Ltd currently shows a below-average growth signal. The stock trades at a P/E of 55.4 with a market cap of ₹6,097 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ion Exchange (India) Ltd planning capital expenditure?
Roha Plant: Focus on utilizing existing Roha facility capacity with backward integration underway; no major new CAPEX planned immediately, only maintenance and routine CAPEX of Rs.30-40 crores for FY27.
Keep Ion Exchange (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
